Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	163
Overall Study	STARTED	Cariprazine 1.5 mg	160
Overall Study	STARTED	Cariprazine 3.0 mg	165
Overall Study	Received Treatment (Safety Population)	Placebo	158
Overall Study	Received Treatment (Safety Population)	Cariprazine 1.5 mg	157
Overall Study	Received Treatment (Safety Population)	Cariprazine 3.0 mg	165
Overall Study	COMPLETED	Placebo	135
Overall Study	COMPLETED	Cariprazine 1.5 mg	134
Overall Study	COMPLETED	Cariprazine 3.0 mg	134
Overall Study	NOT COMPLETED	Placebo	28
Overall Study	NOT COMPLETED	Cariprazine 1.5 mg	26
Overall Study	NOT COMPLETED	Cariprazine 3.0 mg	31

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02670551/flow